EA035888B1 - Режимы дозирования иммунотерапевтических средств и их комбинаций - Google Patents

Режимы дозирования иммунотерапевтических средств и их комбинаций Download PDF

Info

Publication number
EA035888B1
EA035888B1 EA201890035A EA201890035A EA035888B1 EA 035888 B1 EA035888 B1 EA 035888B1 EA 201890035 A EA201890035 A EA 201890035A EA 201890035 A EA201890035 A EA 201890035A EA 035888 B1 EA035888 B1 EA 035888B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pomalidomide
antibody
elotuzumab
dexamethasone
administered
Prior art date
Application number
EA201890035A
Other languages
English (en)
Russian (ru)
Other versions
EA201890035A1 (ru
Inventor
Кристофер Ли Маллиган
Джастин Блейк Бартлетт
Майкл Дэррон Роббинс
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201890035A1 publication Critical patent/EA201890035A1/ru
Publication of EA035888B1 publication Critical patent/EA035888B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EA201890035A 2015-06-29 2016-06-28 Режимы дозирования иммунотерапевтических средств и их комбинаций EA035888B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562185968P 2015-06-29 2015-06-29
US201562239965P 2015-10-11 2015-10-11
US201562262574P 2015-12-03 2015-12-03
PCT/US2016/039723 WO2017003990A1 (en) 2015-06-29 2016-06-28 Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer

Publications (2)

Publication Number Publication Date
EA201890035A1 EA201890035A1 (ru) 2018-06-29
EA035888B1 true EA035888B1 (ru) 2020-08-27

Family

ID=56409706

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890035A EA035888B1 (ru) 2015-06-29 2016-06-28 Режимы дозирования иммунотерапевтических средств и их комбинаций

Country Status (20)

Country Link
US (2) US10925867B2 (https=)
EP (2) EP3950065A1 (https=)
JP (1) JP6754785B2 (https=)
CN (1) CN107949425A (https=)
BR (1) BR112017027692A2 (https=)
CA (1) CA2990478A1 (https=)
CY (1) CY1124543T1 (https=)
DK (1) DK3313528T3 (https=)
EA (1) EA035888B1 (https=)
ES (1) ES2886657T3 (https=)
HR (1) HRP20211478T1 (https=)
HU (1) HUE056491T2 (https=)
LT (1) LT3313528T (https=)
MX (1) MX391581B (https=)
PL (1) PL3313528T3 (https=)
PT (1) PT3313528T (https=)
RS (1) RS62352B1 (https=)
SI (1) SI3313528T1 (https=)
SM (1) SMT202100567T1 (https=)
WO (1) WO2017003990A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015305449B2 (en) * 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
RS62352B1 (sr) * 2015-06-29 2021-10-29 Bristol Myers Squibb Co Imunoterapijski režimi doziranja koji obuhvataju pomalidomid i anti-cs1 antitelo za lečenje kancera
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019376A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2008019378A1 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US8673939B2 (en) * 2002-05-17 2014-03-18 Celgene Corporation Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
WO2016070089A2 (en) * 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA204125A (en) 1920-09-21 Sylvester Pratt Edwin Gramophone operated toy
US819826A (en) 1905-12-14 1906-05-08 Frank R Welcher Stanchion.
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CZ301498B6 (cs) 1999-02-22 2010-03-24 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epothilony
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
CA2752124A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US6958115B2 (en) 2003-06-24 2005-10-25 The United States Of America As Represented By The Secretary Of The Navy Low temperature refining and formation of refractory metals
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CN101534860B (zh) * 2006-08-07 2013-03-27 艾伯特生物治疗学公司 使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法
EP2069478A2 (en) 2006-08-07 2009-06-17 PDL BioPharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
EP2361263A1 (en) 2008-10-31 2011-08-31 Abbott Biotherapeutics Corp. Use of anti-cs1 antibodies for treatment of rare lymphomas
BRPI1007855B1 (pt) 2009-05-19 2020-03-10 Celgene Corporation Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
EP2493485A1 (en) 2009-10-30 2012-09-05 University Of Arkansas For Medical Science Use of autologous effector cells for treatment of multiple myeloma
WO2011053322A1 (en) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
US9506481B1 (en) 2013-01-31 2016-11-29 Daniel Theobald High force hydraulic actuator
US20160331698A1 (en) * 2014-01-13 2016-11-17 University Of Central Florida Research Foundation, Inc. Fullerene compounds as antioxidant therapy
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
RS62352B1 (sr) * 2015-06-29 2021-10-29 Bristol Myers Squibb Co Imunoterapijski režimi doziranja koji obuhvataju pomalidomid i anti-cs1 antitelo za lečenje kancera

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673939B2 (en) * 2002-05-17 2014-03-18 Celgene Corporation Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
WO2008019376A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2008019378A1 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
WO2016070089A2 (en) * 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EFSTATHIOS KASTRITIS, ANDREAS CHARIDIMOU, ANDREAS VARKARIS, MELETIOS A. DIMOPOULOS: "Targeted therapies in multiple myeloma", TARGETED ONCOLOGY, SPRINGER-VERLAG FRANCE, vol. 4, no. 1, 1 March 2009 (2009-03-01), pages 23 - 36, XP055035055, ISSN: 17762596, DOI: 10.1007/s11523-008-0102-9 *
Jesus San Miguel ET AL.: "164962-176", 6 June 2016 (2016-06-06), XP55294897, http://meetinglibrary.asco.org/content/164 962-176 Retrieved from the Internet: URL:http://meetinglibrary.asco.org/print/2 401331 [retrieved on 2016-08-10] the whole document *
KUMAR, S. ; RAJKUMAR, S.V.: "Thalidomide and lenalidomide in the treatment of multiple myeloma", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL, vol. 42, no. 11, 1 July 2006 (2006-07-01), AMSTERDAM, NL, pages 1612 - 1622, XP027964121, ISSN: 0959-8049 *
SZMANIA SUSANN; GREENWAY AMY D; LINGO JOSHUAH D; STONE KATIE; KHAN JUNAID; GARG TARUN K; PETTY NATHAN M; PANOZZO SUSAN B; WOODS EM: "Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity", BLOOD, THE AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 122, no. 21, 1 November 2013 (2013-11-01), US, pages 5389, XP009191317, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
MX391581B (es) 2025-03-04
LT3313528T (lt) 2021-10-11
US20210154183A1 (en) 2021-05-27
RS62352B1 (sr) 2021-10-29
CY1124543T1 (el) 2022-07-22
JP6754785B2 (ja) 2020-09-16
CN107949425A (zh) 2018-04-20
US10925867B2 (en) 2021-02-23
SI3313528T1 (sl) 2021-11-30
EA201890035A1 (ru) 2018-06-29
DK3313528T3 (da) 2021-09-20
JP2018522881A (ja) 2018-08-16
MX2017015765A (es) 2018-04-13
PL3313528T3 (pl) 2021-12-13
EP3313528A1 (en) 2018-05-02
EP3313528B1 (en) 2021-08-04
HRP20211478T1 (hr) 2021-12-24
EP3950065A1 (en) 2022-02-09
US20180185348A1 (en) 2018-07-05
CA2990478A1 (en) 2017-01-05
BR112017027692A2 (pt) 2018-10-09
ES2886657T3 (es) 2021-12-20
HUE056491T2 (hu) 2022-02-28
WO2017003990A1 (en) 2017-01-05
SMT202100567T1 (it) 2021-11-12
PT3313528T (pt) 2021-09-16

Similar Documents

Publication Publication Date Title
JP2022058698A (ja) 抗ｐｄ－１抗体と他の抗癌剤の組合せを使用する腎癌の処置
TWI821748B (zh) 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
JP2022115924A (ja) グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
JP2020117524A (ja) 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
US20130064831A1 (en) Immunotherapeutic dosing regimens and combinations thereof
US20090311187A1 (en) Methods for predicting patient response to modulation of the Co-stimulatory pathway
KR20190007046A (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
US20160264670A1 (en) Immunotherapeutic dosing regimens and combinations thereof
JP2020508317A (ja) 肺癌の処置のための抗ｐｄ−１抗体
US20170355768A1 (en) Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
US20230248855A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
US20220143228A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
US20210154183A1 (en) Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
US20250205375A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
KR20230026492A (ko) Pd-1 길항제, hif-2 알파 억제제 및 렌바티닙 또는 그의 제약상 허용되는 염의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법
AU2021382717A9 (en) Her3 radioimmunotherapy for the treatment of solid cancers
EP4637821A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM